Taro Pharmaceutical Industries Ltd. (TARO) — Financial statements
Income statement, balance sheet, and cash flow for Taro Pharmaceutical Industries Ltd. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 629↑9.8% | 573↑2.1% | 561↑2.3% | 549↓14.9% | 645 | |
| Cost of Revenue | 324↑6.4% | 305↑13.6% | 268↑6.3% | 252↑3.0% | 245 | |
| Gross Profit | 305↑13.7% | 268↓8.5% | 293↓1.2% | 297↓25.8% | 400 | |
| Operating Expenses | ||||||
| R&D Expenses | 65↑23.5% | 52↓4.2% | 55↓9.3% | 60↑0.6% | 60 | |
| General & Administrative Expenses | 0.00↓100.0% | 85↑49.1% | 57↑8.0% | 53↓6.9% | 57 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 113↑100.1% | 57↑46.9% | 39↑5.1% | 37 | |
| SG&A Expenses | 219↑10.4% | 198↑74.5% | 114↑24.4% | 91↓2.2% | 93 | |
| Other Expenses | 0.00↓100.0% | 2 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 283↑13.1% | 251↑49.0% | 168↑11.0% | 152↓1.1% | 153 | |
| Total Costs & Expenses | 608↑9.4% | 555↑27.2% | 436↑8.1% | 404↑1.4% | 398 | |
| Operating Results | ||||||
| Operating Income | 22↑21.4% | 18↓90.4% | 184↓73.8% | 704↑185.7% | 247 | |
| Depreciation & Amortization | 31↓11.0% | 35↑34.8% | 26↑9.4% | 24↑261.7% | 7 | |
| EBITDA | 38↓30.8% | 55↓66.4% | 165↑139.8% | -414↓235.5% | 305 | |
| EBIT | 7↓64.4% | 21↓85.4% | 141↑136.2% | -390↓230.4% | 299 | |
| Interest & Other Income | ||||||
| Net Interest Income | 56↑169.5% | 21↑219.1% | 7↓65.3% | 19↓42.9% | 33 | |
| Interest Income | 56↑154.2% | 22↑170.0% | 8↓59.4% | 20↓40.0% | 34 | |
| Interest Expense | 0.00↓100.0% | 1↓24.2% | 2↑21.3% | 1↑88.0% | 0.73 | |
| Non-Operating Income | 0.00↑100.0% | -3↑82.5% | -16↓103.0% | 535↑1124.1% | -52 | |
| Other Income / Expenses | 75↑267.6% | 20↑143.6% | -47↑91.2% | -536↓1147.5% | 51 | |
| Income Before Tax | 83↑116.3% | 38↓50.9% | 78↑119.9% | -391↓231.4% | 298 | |
| Income Tax Expense | 29↑125.6% | 13↓34.8% | 20↑102.7% | 10↓81.9% | 53 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 54↑111.7% | 25↓56.3% | 58↑114.5% | -401↓264.1% | 244 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 54↑111.7% | 25↓56.3% | 58↑114.5% | -401↓264.1% | 244 | |
| Bottom-Line Net Income | 54↑111.7% | 25↓56.3% | 58↑114.5% | -401↓264.1% | 244 | |
| EPS (Basic) | 1.43↑110.3% | 0.68↓56.1% | 1.55↑114.8% | -10.49↓265.2% | 6.35 | |
| EPS (Diluted) | 1.43↑110.3% | 0.68↓56.1% | 1.55↑114.8% | -10.49↓265.2% | 6.35 | |
| Weighted Average Shares | 38↑0.0% | 38↓0.1% | 38↓1.5% | 38↓0.7% | 38 | |
| Weighted Average Diluted Shares | 38↑0.0% | 38↓0.1% | 38↓1.5% | 38↓0.7% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.